<SEC-DOCUMENT>0001193125-18-353923.txt : 20181220
<SEC-HEADER>0001193125-18-353923.hdr.sgml : 20181220
<ACCEPTANCE-DATETIME>20181220082505
ACCESSION NUMBER:		0001193125-18-353923
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181220
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181220
DATE AS OF CHANGE:		20181220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		181244687

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d679728d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;20, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-31791</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">04-3562325</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Registrant&#146;s telephone number, including area code:<B> (678) <FONT STYLE="white-space:nowrap">620-3186</FONT></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT
STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 8 &#150; OTHER ITEMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Items. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;20, 2018, the Company issued the press release attached hereto as Exhibit 99.1.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d679728dex991.htm">Press release </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: December&nbsp;20, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jack W. Callicutt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack W. Callicutt</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d679728dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g679728image000190.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Announces Extension of $10 Million Line Credit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NORCROSS, Ga. (December 20, 2018)</B> &#150; Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin
proteins, today announced that its $10&nbsp;million unsecured line of credit entered into on December&nbsp;19, 2017, has been extended by one year for both borrowings and maturity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The line of credit arrangement with Richard E. Uihlein, Chairman of the Board of Directors and a shareholder, originally provided for borrowings to occur
through December&nbsp;31, 2018, with all principal and any interest maturing and coming due on December&nbsp;31, 2019. The amendment extends the date for borrowings through December&nbsp;31, 2019, and extends maturity of principal and interest to
December&nbsp;31, 2020. To date, there have been no borrowings under the line of credit. Borrowings bear interest at the Applicable Federal Rate for short term loans published by the Internal Revenue Service (2.09&nbsp;percent on December&nbsp;19,
2018). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harold H. Shlevin, Ph.D., President and Chief Executive Officer of&nbsp;Galectin Therapeutics, said, &#147;We appreciate Mr.&nbsp;Uihlein&#146;s
continued support for the Company and his willingness to extend the line of credit.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard E. Uihlein added, &#147;I remain committed to the
Company and am pleased with the progress Dr.&nbsp;Shlevin and the team are making as evidenced by extending the line of credit.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin
Therapeutics&nbsp;is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin&#146;s lead drug <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GR-MD-02)</FONT></FONT>
is a carbohydrate-based drug that inhibits the <FONT STYLE="white-space:nowrap">galectin-3</FONT> protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in <FONT
STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today.
Additional development programs are in treatment of severe atopic dermatitis, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> plaque psoriasis, and in combination immunotherapy for advanced melanoma
and other malignancies; advancement of these additional clinical programs is largely dependent on finding a suitable partner and/or obtaining significant additional financing. Galectin seeks to leverage extensive scientific and development expertise
as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at<B><U>&nbsp;www.galectintherapeutics.com</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>1</B> of <B>2</B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to
future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on management&#146;s current expectations and are subject to factors and
uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin&#146;s development program for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in the treatment of severe atopic
dermatitis, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> plaque psoriasis and in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ
materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> or any of its other drugs in development; the Company may encounter unexpected difficulties in obtaining approval for its Phase 3 clinical trials in the area of fatty liver disease; the Company may
not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company&#146;s future clinical studies may not produce positive results in a timely fashion, if at all, and could
prove time consuming and costly; plans regarding development, approval and marketing of any of Galectin&#146;s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies;
regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting
Galectin&#146;s business, see the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and subsequent filings with the SEC. You should not place undue reliance on
forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack Callicutt, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(678) <FONT STYLE="white-space:nowrap">620-3186</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@galectintherapeutics.com. </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics and
its associated logo is a registered trademark of Galectin Therapeutics Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;# </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>2</B> of <B>2</B> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g679728image000190.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g679728image000190.jpg
M_]C_X  02D9)1@ ! 0$ ;0!M  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M^B1ZI9QND$DDB*'ZG8Q4G]*VJ\]^ T;V_P --.AD'S1R3HV?42M7H&0.IZT
M.S378KC I"W3%+D&@#S3XB_%6Z\%7)BN/#5R\3L5ANFE41RX^G-=WX=U!]6T
M+3]1DC$;7=O'.4!R%+*#C]:\I_:F^7PEIC#K]LX_[Y->E^ O^1)T+_KP@_\
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M+HC,0%&GPDD]AY8KS?\ :I_Y%#3/^OP_^@FNNW3)\% UKGS_ .PALQUSY'%
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MT%R A)S@"N1\;:3:^/\ P'<VMC,)$NT$MO(#QO4_+^HQ0!\;9).6SCTKZ/\
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M5]I\EE:1P2-<J/+DPNTX(/.0.XKL\<5D:U#JUQ<6RZ7=16L66,[M$)&QCY0
M3CKGUH \GTKPUK?PJ\7SW^C:?-JOAR^XEC@.98>>/E/7'KW%=H?'LVIP-#X:
MT/4KN]?A/M$#011GU=F[#VS5;1K_ ,4ZO%KB6>J6WGZ9>-:Q(]J LNW!&XYX
MSTS6GJWB.;2O&VGV%W<01:=<6<LS[Q@JZ%0/F_&@=BY%X<>]\&-H?B&[DU&2
MXB9+F=ARS,2?E] ">/8"O-?!5OX@^$E]>:7J.G76J:!<R>;%=6:%VC;&,E?<
M 9'M7L?]IV7V%;[[5#]E8!A,'&T@].:B.MZ8MG]K:_MUMB^P2&0!=W3&?7-
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9BLHTE%W1WXC'5,1!0GL@'6EH Q16IP'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
